{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:59:01Z","timestamp":1791968341458,"version":"4.3.4"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejca.2025.115403","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T10:01:45Z","timestamp":1743933705000},"page":"115403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Mapping the potential for anti-PD-1 therapy in advanced rare skin carcinomas"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4832-3410","authenticated-orcid":false,"given":"Clio","family":"Dessinioti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Stratigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115403_bib1","unstructured":"EURACAN. Rare cancer of the skin and eye melanoma. Accessed on November 3, 2024. https:\/\/euracan.eu\/rare-adult-solid-cancers\/skin-eye-melanoma\/."},{"key":"10.1016\/j.ejca.2025.115403_bib2","volume":"11","author":"Elder","year":"2018"},{"key":"10.1016\/j.ejca.2025.115403_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljad033","article-title":"\"Get Data Out\" skin: national cancer registry incidence and survival rates for all registered skin tumour groups for 2013-2019 in England","author":"van Bodegraven","year":"2023","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115403_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jaad.2022.04.052","article-title":"Incidence and trends of cutaneous adnexal tumors in the United States in 2000-2018: a population-based study","volume":"88","author":"Gibbs","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2025.115403_bib5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115403_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113254","article-title":"European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023","volume":"192","author":"Peris","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115403_bib7","article-title":"European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023","volume":"193","author":"Stratigos","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115403_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115121","article-title":"An updated review of immune checkpoint inhibitors in cutaneous oncology: beyond melanoma","volume":"214","author":"Pham","year":"2025","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2025.115403_bib9","first-page":"730","article-title":"S1-Guideline Sebaceous Carcinoma","volume":"22","author":"Utikal","year":"2024","journal-title":"J Der Dtsch Dermatol Ges =\u202fJ Ger Soc Dermatol: JDDG"},{"key":"10.1016\/j.ejca.2025.115403_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jdin.2024.03.012","article-title":"Sebaceous carcinoma of the trunk and extremities: epidemiology and treatment patterns in the United States","volume":"16","author":"Grunvald","year":"2024","journal-title":"JAAD Int"},{"issue":"2","key":"10.1016\/j.ejca.2025.115403_bib11","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3390\/curroncol30020109","article-title":"Pilomatrix carcinoma: report of two cases of the head and review of the literature","volume":"30","author":"Toffoli","year":"2023","journal-title":"Curr Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2025.115403_bib12","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/archderm.136.11.1355","article-title":"Microcystic adnexal carcinoma: forty-eight cases, their treatment, and their outcome","volume":"136","author":"Chiller","year":"2000","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115403_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14559","article-title":"Microcystic adnexal carcinoma of the head and neck: characteristics, treatment, and survival statistics","volume":"34","author":"Behbahani","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejca.2025.115403_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.amsu.2017.06.027","article-title":"Porocarcinoma; presentation and management, a meta-analysis of 453 cases","volume":"20","author":"Salih","year":"2017","journal-title":"Ann Med Surg"},{"issue":"9","key":"10.1016\/j.ejca.2025.115403_bib15","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1002\/hed.26178","article-title":"Eccrine porocarcinoma of the head and neck: meta-analysis of 120 cases","volume":"42","author":"Le","year":"2020","journal-title":"Head Neck"},{"issue":"2","key":"10.1016\/j.ejca.2025.115403_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ced\/llac052","article-title":"Variation in management of porocarcinoma: a 10-year retrospective review of 75 cases across three UK tertiary centres","volume":"48","author":"Winn","year":"2023","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115403_bib17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jdermsci.2016.06.004","article-title":"A proposal for a TNM staging system for extramammary Paget disease: retrospective analysis of 301 patients with invasive primary tumors","volume":"83","author":"Ohara","year":"2016","journal-title":"J Dermatol Sci"},{"issue":"1","key":"10.1016\/j.ejca.2025.115403_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaad.2023.08.088","article-title":"Therapeutic outcomes and survival analysis of Extramammary Paget's disease: a multicentre retrospective study of 249 patients","volume":"90","author":"Escola","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.ejca.2025.115403_bib19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s00262-024-03846-8","article-title":"Immunotherapy may be more appropriate for ERBB2 low-expressing extramammary paget's disease patients: a prognosis analysis and exploration of targeted therapy and immunotherapy of extramammary paget's disease patients","volume":"73","author":"Yang","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2025.115403_bib20","article-title":"Systematic analysis and case series of the diagnosis and management of trichilemmal carcinoma","volume":"12","author":"Sun","year":"2022","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2025.115403_bib21","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00403-024-03457-4","article-title":"Trichilemmal carcinoma: surgical outcomes with wide local excision versus Mohs micrographic surgery","volume":"316","author":"Shahinfar","year":"2024","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"10.1016\/j.ejca.2025.115403_bib22","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1002\/dc.25279","article-title":"Trichilemmal carcinoma metastatic to parotid gland: first report of fine needle aspiration cytology features","volume":"52","author":"Jayakumar","year":"2024","journal-title":"Diagn Cytopathol"},{"issue":"10","key":"10.1016\/j.ejca.2025.115403_bib23","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/1750743X.2024.2353535","article-title":"Successful treatment of trichilemmal carcinoma with distant metastasis using pembrolizumab: a case report and review","volume":"16","author":"Liu","year":"2024","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.ejca.2025.115403_bib24","first-page":"313","article-title":"Extramammary paget's disease: treatment, prognostic factors and outcome in 76 patients","volume":"158","author":"Hatta","year":"2008","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115403_bib25","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/s12885-020-07009-7","article-title":"The molecular pathogenesis of trichilemmal carcinoma","volume":"20","author":"Ha","year":"2020","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.115403_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaad.2009.07.027","article-title":"Primary cutaneous adenoid cystic carcinoma in the United States: incidence, survival, and associated cancers, 1976 to 2005","volume":"63","author":"Dores","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.ejca.2025.115403_bib27","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1097\/PAS.0b013e318299fcac","article-title":"Primary cutaneous adenoid cystic carcinoma: a clinicopathologic and immunohistochemical study of 27 cases","volume":"37","author":"Ramakrishnan","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115403_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00403-022-02323-5","article-title":"Reappraisal and literature review of primary cutaneous cribriform apocrine carcinoma","volume":"315","author":"Davis","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"11","key":"10.1016\/j.ejca.2025.115403_bib29","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/ced\/llae203","article-title":"National epidemiology of digital papillary adenocarcinoma in England 2013-2020: a population-based registry study","volume":"49","author":"Andrew","year":"2024","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115403_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0560.1987.tb00488.x","article-title":"Aggressive digital papillary adenoma and adenocarcinoma. A clinicopathological study of 57 patients, with histochemical, immunopathological, and ultrastructural observations","volume":"14","author":"Kao","year":"1987","journal-title":"J Cutan Pathol"},{"issue":"9","key":"10.1016\/j.ejca.2025.115403_bib31","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/DSS.0000000000002263","article-title":"Prognostic factors, treatment, and survival in primary cutaneous mucinous carcinoma: a SEER database analysis","volume":"46","author":"Rismiller","year":"2020","journal-title":"Dermatol Surg"},{"issue":"3","key":"10.1016\/j.ejca.2025.115403_bib32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jaad.2017.02.028","article-title":"Aggressive digital papillary adenocarcinoma: a clinicopathological study of 19 cases","volume":"77","author":"Weingertner","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115403_bib33","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/DAD.0000000000002591","article-title":"Primary mucinous carcinoma of skin: a rare cutaneous neoplasm. clinicopathologic features, differential diagnoses, and review of literature","volume":"46","author":"Tinguria","year":"2024","journal-title":"Am J Derm"},{"issue":"12","key":"10.1016\/j.ejca.2025.115403_bib34","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1093\/ced\/llae317","article-title":"Epidemiology, survival and risk of subsequent primary malignancies in patients with digital papillary adenocarcinoma: a retrospective study of 213 patients in the surveillance, epidemiology, and end results program","volume":"49","author":"Joshi","year":"2024","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115403_bib35","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/jamadermatol.2013.6006","article-title":"Primary cutaneous mucinous carcinoma: a systematic review and meta-analysis of outcomes after surgery","volume":"150","author":"Kamalpour","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.ejca.2025.115403_bib36","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1111\/ans.16626","article-title":"Challenges in diagnosis and management of a spiradenocarcinoma: a comprehensive literature review","volume":"91","author":"Wagner","year":"2021","journal-title":"ANZ J Surg"},{"issue":"5","key":"10.1016\/j.ejca.2025.115403_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12052045","article-title":"Spiradenocarcinoma: SEER study of epidemiology, survival, and treatment options","volume":"12","author":"Martineau","year":"2023","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.ejca.2025.115403_bib38","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/ijd.16129","article-title":"Porocarcinoma: an epidemiological, clinical, and dermoscopic 20-year study","volume":"61","author":"De Giorgi","year":"2022","journal-title":"Int J Dermatol"},{"issue":"11","key":"10.1016\/j.ejca.2025.115403_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25115760","article-title":"Porocarcinoma: clinical and histological features, immunohistochemistry and outcomes: a systematic review","volume":"25","author":"Bienstman","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2025.115403_bib40","article-title":"Primary cutaneous cribriform tumor: a case report and literature review","author":"Jiang","year":"2024","journal-title":"J Cutan Pathol"},{"issue":"9","key":"10.1016\/j.ejca.2025.115403_bib41","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamadermatol.2019.1251","article-title":"Evidence-based clinical practice guidelines for microcystic adnexal carcinoma: informed by a systematic review","volume":"155","author":"Worley","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2025.115403_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.20444","article-title":"Prognosis of primary cutaneous angiosarcoma versus radiation-induced angiosarcoma: a cohort study","author":"Utikal","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115403_bib43","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamaoto.2014.3584","article-title":"Angiosarcoma of the scalp and face: the mayo clinic experience","volume":"141","author":"Patel","year":"2015","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"2","key":"10.1016\/j.ejca.2025.115403_bib44","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.anndiagpath.2010.07.012","article-title":"Cutaneous angiosarcoma. Analysis of 434 cases from the surveillance, epidemiology, and end results program, 1973-2007","volume":"15","author":"Albores-Saavedra","year":"2011","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115403_bib45","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jaad.2019.10.070","article-title":"Survival and demographic differences of periocular and nonperiocular sebaceous carcinomas","volume":"83","author":"Liszewski","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.ejca.2025.115403_bib46","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jaad.2016.07.046","article-title":"Incidence and survival of sebaceous carcinoma in the United States","volume":"75","author":"Tripathi","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115403_bib47","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jaad.2023.03.032","article-title":"Comparison of clinicopathologic features, survival, and demographics in sebaceous carcinoma patients with and without muir-torre syndrome","volume":"89","author":"Maloney","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2025.115403_bib48","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.bjps.2023.11.039","article-title":"Clinical characteristics and treatment outcomes of angiosarcoma of the head and neck: A 17-year single-centre experience","volume":"88","author":"Evans","year":"2024","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"7","key":"10.1016\/j.ejca.2025.115403_bib49","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/DSS.0000000000004174","article-title":"Cutaneous angiosarcoma subtypes: a quantitative systematic review of demographics, treatments, and outcomes within published patient-level cases","volume":"50","author":"Kwapnoski","year":"2024","journal-title":"Dermatol Surg"},{"issue":"6","key":"10.1016\/j.ejca.2025.115403_bib50","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/lio2.1173","article-title":"Cutaneous head and neck angiosarcoma: the 30-year UCLA experience","volume":"8","author":"Evans","year":"2023","journal-title":"Laryngoscope Invest Otolaryngol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115403_bib51","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s12282-023-01535-5","article-title":"Radiation-induced angiosarcoma of the breast: retrospective analysis at a regional treatment centre","volume":"31","author":"Wong","year":"2024","journal-title":"Breast Cancer"},{"issue":"17","key":"10.1016\/j.ejca.2025.115403_bib52","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res Official J Am Assoc Cancer Res"},{"issue":"10","key":"10.1016\/j.ejca.2025.115403_bib53","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/s41588-024-01899-0","article-title":"Five latent factors underlie response to immunotherapy","volume":"56","author":"Usset","year":"2024","journal-title":"Nat Genet"},{"issue":"6230","key":"10.1016\/j.ejca.2025.115403_bib54","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.ejca.2025.115403_bib55","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2025.115403_bib56","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.ejca.2025.115403_bib57","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1111\/1346-8138.17101","article-title":"Unfavorable efficacy of pembrolizumab for advanced extramammary Paget's disease with high tumor mutation burden after failure of taxane-based regimens","volume":"51","author":"Koizumi","year":"2024","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115403_bib58","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1159\/000514345","article-title":"Treatment of metastatic extramammary paget disease with combination ipilimumab and nivolumab: a case report","volume":"14","author":"Guercio","year":"2021","journal-title":"Case Rep Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115403_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002990","article-title":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","volume":"9","author":"Wagner","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2025.115403_bib60","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/1078-0432.CCR-20-2473","article-title":"Sebaceous carcinoma epidemiology and genetics: emerging concepts and clinical implications for screening, prevention, and treatment","volume":"27","author":"Sargen","year":"2021","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2025.115403_bib61","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1038\/s41467-018-04008-y","article-title":"Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma","volume":"9","author":"North","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ejca.2025.115403_bib62","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/his.14441","article-title":"Molecular pathology of skin adnexal tumours","volume":"80","author":"Plotzke","year":"2022","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.ejca.2025.115403_bib63","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40425-018-0357-3","article-title":"Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma","volume":"6","author":"Domingo-Musibay","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.115403_bib64","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/path.4759","article-title":"Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma","volume":"240","author":"Tetzlaff","year":"2016","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115403_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030476","article-title":"Recent advances on immunohistochemistry and molecular biology for the diagnosis of adnexal sweat gland tumors","volume":"14","author":"Macagno","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.ejca.2025.115403_bib66","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/bjd.20604","article-title":"High tumour mutational burden and EGFR\/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma","volume":"185","author":"Westphal","year":"2021","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.ejca.2025.115403_bib67","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41417-021-00347-z","article-title":"Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies","volume":"29","author":"Denisova","year":"2022","journal-title":"Cancer Gene Ther"},{"issue":"6","key":"10.1016\/j.ejca.2025.115403_bib68","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1158\/1078-0432.CCR-20-3205","article-title":"Unbiased detection of driver mutations in extramammary paget disease","volume":"27","author":"Ishida","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2025.115403_bib69","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jaad.2023.11.057","article-title":"Mutational landscape of advanced extramammary paget disease with comprehensive genomic profiling tests: a cohort study in a Japanese real-world setting","volume":"90","author":"Iwasawa","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.ejca.2025.115403_bib70","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1111\/1346-8138.16898","article-title":"Treatment of high tumor mutation burden metastatic extramammary paget disease with an anti-PD-1 antibody","volume":"50","author":"Nakayama","year":"2023","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115403_bib71","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/cam4.2820","article-title":"Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary paget's disease","volume":"9","author":"Gatalica","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2025.115403_bib72","article-title":"Histologic and genomic characterization of a primary mucinous carcinoma of the skin","volume":"1","author":"Papanastasiou","year":"2023","journal-title":"EJC Ski Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2025.115403_bib73","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41591-019-0749-z","article-title":"The angiosarcoma project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research","volume":"26","author":"Painter","year":"2020","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.ejca.2025.115403_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235938","article-title":"Immunological and genomic analysis reveals clinically relevant distinctions between angiosarcoma subgroups","volume":"14","author":"van Ravensteijn","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.ejca.2025.115403_bib75","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004149","article-title":"Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center","volume":"10","author":"Rosenbaum","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2025.115403_bib76","doi-asserted-by":"crossref","first-page":"797","DOI":"10.6004\/jnccn.2018.7018","article-title":"Response to checkpoint inhibitor therapy in advanced classic kaposi sarcoma: a case report and immunogenomic study","volume":"16","author":"Saller","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.ejca.2025.115403_bib77","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2326-6066.CIR-18-0121","article-title":"Successful treatment of HIV-associated kaposi sarcoma with immune checkpoint blockade","volume":"6","author":"Galanina","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.ejca.2025.115403_bib78","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(22)00097-3","article-title":"PD-1 blockade with pembrolizumab in classic or endemic kaposi's sarcoma: a multicentre, single-arm, phase 2 study","volume":"23","author":"Delyon","year":"2022","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2025.115403_bib79","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1111\/jdv.18463","article-title":"Genetic landscape of indolent and aggressive kaposi sarcomas","volume":"36","author":"Malouf","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.ejca.2025.115403_bib80","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00262-019-02334-8","article-title":"Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas","volume":"68","author":"Duverger","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2025.115403_bib81","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ajo.2020.07.031","article-title":"High expression of programmed death ligand 1 and programmed death ligand 2 in ophthalmic sebaceous carcinoma: the case for a clinical trial of checkpoint inhibitors","volume":"220","author":"Wolkow","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ejca.2025.115403_bib82","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1475874","article-title":"High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma","volume":"7","author":"Kandl","year":"2018","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.ejca.2025.115403_bib83","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1111\/aos.13833","article-title":"Programmed death receptor ligand 1 expression in eyelid sebaceous carcinoma: a consecutive case series of 41 patients","volume":"97","author":"Xu","year":"2019","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"10.1016\/j.ejca.2025.115403_bib84","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s00262-020-02821-3","article-title":"PD-L1 expression in sebaceous carcinomas","volume":"70","author":"Saliba","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.ejca.2025.115403_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060754","article-title":"Expression of PD-1 and PD-L1 in Extramammary paget disease: implications for immune-targeted therapy","volume":"11","author":"Mauzo","year":"2019","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.ejca.2025.115403_bib86","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00262-018-2189-x","article-title":"Expression of CD3, PD-L1 and CTLA-4 in mammary and extra-mammary paget disease","volume":"67","author":"Karpathiou","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"58","key":"10.1016\/j.ejca.2025.115403_bib87","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.18632\/oncotarget.27247","article-title":"Extramammary paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer\/testis antigens NY-ESO-1 and MAGE-A","volume":"10","author":"Pourmaleki","year":"2019","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ejca.2025.115403_bib88","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/DAD.0000000000001622","article-title":"PD-L1 expression in extramammary paget disease: a case series","volume":"43","author":"Fowler","year":"2021","journal-title":"Am J Derm"},{"issue":"4","key":"10.1016\/j.ejca.2025.115403_bib89","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","article-title":"Electronic address edsc, Cancer genome atlas research N. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas","volume":"171","author":"Cancer Genome Atlas Research Network","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ejca.2025.115403_bib90","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0000000000000317","article-title":"Expression of programmed cell death proteins in kaposi sarcoma and cutaneous angiosarcoma","volume":"43","author":"Gambichler","year":"2020","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.ejca.2025.115403_bib91","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1253657","article-title":"Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma","volume":"6","author":"Honda","year":"2017","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.ejca.2025.115403_bib92","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1200\/JGO.2016.005843","article-title":"Positive PD-L1 expression predicts worse outcome in cutaneous angiosarcoma","volume":"3","author":"Shimizu","year":"2017","journal-title":"J Glob Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115403_bib93","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s12026-021-09259-4","article-title":"Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups","volume":"70","author":"Tomassen","year":"2022","journal-title":"Immunol Res"},{"issue":"8","key":"10.1016\/j.ejca.2025.115403_bib94","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/DAD.0000000000001843","article-title":"Immune checkpoint markers in superficial angiosarcomas: PD-L1, PD-1, CD8, LAG-3, and tumor-infiltrating lymphocytes","volume":"43","author":"Googe","year":"2021","journal-title":"Am J Derm"},{"issue":"5","key":"10.1016\/j.ejca.2025.115403_bib95","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.3390\/curroncol30050388","article-title":"PD-L1 expression in cutaneous angiosarcomas: a systematic review with meta-analysis","volume":"30","author":"Lobrano","year":"2023","journal-title":"Curr Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115403_bib96","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12032-016-0807-z","article-title":"Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas","volume":"33","author":"Paydas","year":"2016","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115403_bib97","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/cup.13841","article-title":"PD-1 and PD-L1 expression in kaposi sarcoma: a comparative study according to the pathological stage and clinical characteristics","volume":"48","author":"Kim","year":"2021","journal-title":"J Cutan Pathol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115403_bib98","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1684\/ejd.2024.4697","article-title":"Successful treatment of aggressive metastatic sebaceous carcinoma with pembrolizumab","volume":"34","author":"Jikihara","year":"2024","journal-title":"Eur J Dermatol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115403_bib99","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1097\/IOP.0000000000001164","article-title":"Carboplatin and pembrolizumab chemoimmunotherapy achieves remission in recurrent, metastatic sebaceous carcinoma","volume":"34","author":"Kodali","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ejca.2025.115403_bib100","article-title":"Excellent response to cemiplimab and radiotherapy in advanced metastatic porocarcinoma","author":"Abu Rached","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2025.115403_bib101","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdcr.2024.01.038","article-title":"Metastatic porocarcinoma: a case demonstrating objective response to pembrolizumab","volume":"50","author":"Benhayoun","year":"2024","journal-title":"JAAD case Rep"},{"issue":"9","key":"10.1016\/j.ejca.2025.115403_bib102","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-228917","article-title":"Metastatic porocarcinoma achieving complete radiological and clinical response with pembrolizumab","volume":"12","author":"Lee","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"11","key":"10.1016\/j.ejca.2025.115403_bib103","article-title":"Metastatic porocarcinoma effectively managed by pembrolizumab","volume":"13","author":"Singh","year":"2021","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.ejca.2025.115403_bib104","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1200\/PO.20.00285","article-title":"Response to PD-1 immunotherapy in metastatic spiradenocarcinoma","author":"Wu","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2025.115403_bib105","first-page":"1","article-title":"Metastatic spiradenocarcinoma managed with PD-1 inhibition","author":"Wargo","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2025.115403_bib106","article-title":"Treatment of metastatic primary extramammary paget disease with combination anlotinib and tislelizumab: a case report and review of the literature","volume":"9","author":"Yin","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ejca.2025.115403_bib107","article-title":"Case report: disitamab vedotin combined with immunotherapy demonstrated excellent efficacy in scrotal paget's disease with Her-2 overexpression","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.ejca.2025.115403_bib108","article-title":"A case of advanced extramammary paget's disease with a high tumor mutation burden that showed partial lymph node regression with pembrolizumab","volume":"16","author":"Horisaki","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.ejca.2025.115403_bib109","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.17365","article-title":"Efficacy of immune checkpoint inhibitors in patients with metastatic extramammary paget's disease: report of two cases and literature review","author":"Muto","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.ejca.2025.115403_bib110","article-title":"Tislelizumab plus chemotherapy in metastatic extramammary paget disease after surgery: a case report","volume":"14","author":"Wang","year":"2024","journal-title":"Front Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2025.115403_bib111","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1002\/cncr.34370","article-title":"Clinical activity of checkpoint inhibitors in angiosarcoma: a retrospective cohort study","volume":"128","author":"Ravi","year":"2022","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2025.115403_bib112","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/jamaoncol.2019.6152","article-title":"Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial","volume":"6","author":"Kelly","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115403_bib113","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s40425-019-0689-7","article-title":"Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution","volume":"7","author":"Florou","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.115403_bib114","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1038\/s41598-023-30412-6","article-title":"Efficacy and safety of angiogenesis inhibitors plus immune checkpoint inhibitors in advanced soft tissue sarcoma: a real-world, single-center study","volume":"13","author":"Liu","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ejca.2025.115403_bib115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00107","article-title":"Dramatic response of a PD-L1-positive advanced angiosarcoma of the scalp to pembrolizumab","author":"Hamacher","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2025.115403_bib116","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1470-2045(22)00392-8","article-title":"Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial","volume":"23","author":"Somaiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115403_bib117","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejca.2021.04.034","article-title":"Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: a systematic review and meta-analysis","volume":"152","author":"Saerens","year":"2021","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2025.115403_bib118","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1177\/1078155220985589","article-title":"Case of metastatic kaposi sarcoma successfully treated with anti-PD-1 immunotherapy","volume":"27","author":"Cesmeci","year":"2021","journal-title":"J Oncol Pharm Pr"},{"issue":"5","key":"10.1016\/j.ejca.2025.115403_bib119","doi-asserted-by":"crossref","first-page":"442","DOI":"10.6004\/jnccn.2022.7091","article-title":"Anaplastic classic kaposi sarcoma: PD-L1 expression and response to immunotherapy: a case report and review of the literature","volume":"21","author":"Lolli","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"10.1016\/j.ejca.2025.115403_bib120","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.annonc.2022.03.012","article-title":"Phase II single-arm study of nivolumab and ipilimumab (Nivo\/Ipi) in previously treated classical Kaposi sarcoma (cKS)","volume":"33","author":"Zer","year":"2022","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2025.115403_bib121","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-A phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2025.115403_bib122","article-title":"Cancer immunotherapy trials network 12: pembrolizumab in HIV-associated kaposi sarcoma","author":"Lurain","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115403_bib123","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.tics.2014.02.010","article-title":"Publication and other reporting biases in cognitive sciences: detection, prevalence, and prevention","volume":"18","author":"Ioannidis","year":"2014","journal-title":"Trends Cogn Sci"},{"issue":"4","key":"10.1016\/j.ejca.2025.115403_bib124","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1001\/jamaoncol.2021.7148","article-title":"Evidence-based clinical practice guidelines for extramammary paget disease","volume":"8","author":"Kibbi","year":"2022","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2025.115403_bib125","first-page":"1801","article-title":"S1-guideline cutaneous angiosarcomas - update 2021","volume":"19","author":"Vogt","year":"2021","journal-title":"J der Dtsch Dermatol Ges J Ger Soc Dermatol: JDDG"},{"key":"10.1016\/j.ejca.2025.115403_bib126","unstructured":"Reid E., Soneja G., Alexiev B., et al. NCCN Guidelines Version 1.2025. Kaposi sarcoma. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kaposi.pdf. Accessed on 30 November, 2024. 2025."},{"issue":"6","key":"10.1016\/j.ejca.2025.115403_bib127","first-page":"892","article-title":"S1 guidelines for the kaposi sarcoma","volume":"20","author":"Esser","year":"2022","journal-title":"J der Dtsch Dermatol Ges J Ger Soc Dermatol: JDDG"},{"key":"10.1016\/j.ejca.2025.115403_bib128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2018.12.036","article-title":"Diagnosis and treatment of kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF\/EADO\/EORTC)","volume":"114","author":"Lebbe","year":"2019","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2025.115403_bib129","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/ced\/llad122","article-title":"Epidemiology of porocarcinoma in England 2013-2018: a population-based registry study","volume":"48","author":"Joshy","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ejca.2025.115403_bib130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpra.2019.04.003","article-title":"Malignant cylindroma of the scalp treated with staged perimeter excision: A case report and literature review","volume":"21","author":"Kim","year":"2019","journal-title":"JPRAS Open"},{"issue":"6","key":"10.1016\/j.ejca.2025.115403_bib131","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.jaad.2020.05.094","article-title":"Outcomes in patients with extramammary Paget disease with brain metastasis: a retrospective analysis","volume":"83","author":"Fusumae","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115403_bib132","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/bjophthalmol-2019-315490","article-title":"Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma","volume":"105","author":"Singh","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115403_bib133","first-page":"125","article-title":"Metastatic cylindrocarcinoma in Brooke-Spiegler Syndrome - Report of a case and review of the literature","volume":"19","author":"Pichler","year":"2021","journal-title":"J der Dtsch Dermatol Ges J Ger Soc Dermatol JDDG"},{"key":"10.1016\/j.ejca.2025.115403_bib134","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1337400","article-title":"Case report: pilomatrix carcinoma with PDL1 expression and CDKN2A aberrant","volume":"15","author":"Abula","year":"2024","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.ejca.2025.115403_bib135","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clinical Cancer Res Off J Am Assoc Cancer Res"},{"issue":"10","key":"10.1016\/j.ejca.2025.115403_bib136","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/cup.13716","article-title":"Stage-related PD-L1 expression in Kaposi sarcoma tumor microenvironment","volume":"47","author":"Joest","year":"2020","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.ejca.2025.115403_bib137","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.virol.2019.07.024","article-title":"Expression of PD-1 and PD-Ls in kaposi's sarcoma and regulation by oncogenic herpesvirus lytic reactivation","volume":"536","author":"Chen","year":"2019","journal-title":"Virology"},{"issue":"8","key":"10.1016\/j.ejca.2025.115403_bib138","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1304337","article-title":"Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory kaposi's sarcoma: a pilot study","volume":"6","author":"Mletzko","year":"2017","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.ejca.2025.115403_bib139","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/cncr.35110","article-title":"Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS malignancy consortium 095 study","volume":"130","author":"Rajdev","year":"2024","journal-title":"Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:58:06Z","timestamp":1749815886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925001844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":139,"alternative-id":["S0959804925001844"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115403","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mapping the potential for anti-PD-1 therapy in advanced rare skin carcinomas","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115403","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115403"}}